UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. HIV感染症の治療に用いる抗レトロウイルス薬の概要overview of antiretroviral agents used to treat hiv [show details]
… mg dose given with a pharmacokinetic booster has not been established. Tenofovir can lead to kidney injury and bone loss; however TAF is associated with less renal and bone toxicity compared with TDF since …
2. 成人のB型肝炎ワクチン接種hepatitis b virus immunization in adults [show details]
… years received a booster dose of the vaccine; a titer of ≥10 milli-international units/mL was seen in approximately 93 percent six weeks after receiving the booster dose.… individuals, smokers, and men, and significantly lower in patients with diabetes, cirrhosis, chronic renal failure, organ transplant recipients, children with celiac disease, and immunosuppressed patients …
3. 腫瘍学の最新情報whats new in oncology [show details]
…least one risk feature, those assigned to a radiation boost experienced five-year free-from-local-recurrence rates of 97 versus 93 percent in the no boost group (hazard ratio 0.47) . For most women receiving …
4. ウイルス量の増殖を抑制できているHIV-1成人患者への抗レトロウイルス薬の切り替えswitching antiretroviral therapy for adults with hiv 1 and a suppressed viral load [show details]
… TDF has abnormal renal function and/or significant risk factors for TDF-associated renal disease, we petition insurance for the TAF-based option. The combination of TDF plus a boosted protease inhibitor …
5. 成人における肺炎球菌ワクチンpneumococcal vaccination in adults [show details]
… Although it is hypothesized that the immunogenicity of PPSV is boosted by prior administration of PCV, this booster effect has not been convincingly demonstrated .… other conditions associated with altered immunocompetence (functional or anatomic asplenia, chronic renal disease, and nephrotic syndrome) Functional or anatomic asplenia; In addition to the indications …